Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Core Insights - Cellipont Bioservices has entered into a collaboration with Ernexa Therapeutics to advance ERNA-101, a cell therapy for ovarian cancer, into clinical manufacturing and trials [1][2][3] Company Overview - Cellipont Bioservices is a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell therapies, offering comprehensive solutions from process development to large-scale commercial manufacturing [4] - Ernexa Therapeutics focuses on developing innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) [5][6] Technology and Product Development - ERNA-101 is designed to activate and regulate the immune system's response to cancer cells, with the potential to convert "cold" tumors into "hot" tumors, enhancing immune cell infiltration and suppressing tumor growth [3][6] - The collaboration will support the current Good Manufacturing Practice (cGMP) development and scale-up of the ERNA-101 manufacturing process in preparation for clinical trials [3]